PERRIN H. LONG, M.D.; ELEANOR A. BLISS, Sc.D.
This content is PDF only. Please click on the PDF icon to access.
In the Lancet of May 28, 1938, L. E. H. Whitby1 reported that 2 (p-aminobenzenesulphonamido) pyridine (sulfapyridine) was "chemotherapeutically active in experimental infections in mice against pneumococci of types I, II, III, V, VII, VIII and especially against types I, VII and VIII." Whitby also stated in this paper that the drug appeared "to exert a definite action on the capsule of the pneumococcus." Within a very short time after this communication appeared, Evans and Gaisford2 reported that they had treated with sulfapyridine 100 patients suffering from lobar pneumonia, and that in this group of patients the case fatality rate
LONG PH, BLISS EA. OBSERVATIONS UPON THE EXPERIMENTAL USE OF SULFAPYRIDINE. I. THE RELATION OF STRAIN RESISTANCE TO THE CHEMOTHERAPEUTIC EFFECTS OF SULFAPYRIDINE IN EXPERIMENTAL PNEUMOCOCCAL INFECTIONS IN MICE*. Ann Intern Med. 1939;13:232–237. doi: https://doi.org/10.7326/0003-4819-13-2-232
Download citation file:
Published: Ann Intern Med. 1939;13(2):232-237.
Infectious Disease, Streptococcal Infections.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use